These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 21646302)
21. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443 [TBL] [Abstract][Full Text] [Related]
22. [Research progress on the relationship between SLCO1B1 gene and neonatal jaundice]. Lu AF; Zhong DN Zhongguo Dang Dai Er Ke Za Zhi; 2014 Nov; 16(11):1183-7. PubMed ID: 25406570 [TBL] [Abstract][Full Text] [Related]
23. UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association? Alencastro de Azevedo L; Reverbel da Silveira T; Carvalho CG; Martins de Castro S; Giugliani R; Matte U Pediatr Res; 2012 Aug; 72(2):169-73. PubMed ID: 22580719 [TBL] [Abstract][Full Text] [Related]
24. Exploring the genetic architecture of neonatal hyperbilirubinemia. Watchko JF; Lin Z Semin Fetal Neonatal Med; 2010 Jun; 15(3):169-75. PubMed ID: 20022574 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540 [TBL] [Abstract][Full Text] [Related]
27. Genetic Factors and Delayed TSB Monitoring and Treatment as Risk Factors Associated with Severe Hyperbilirubinemia in Term Neonates Admitted for Phototherapy. Boo NY; Sin S; Chee SC; Mohamed M; Ahluwalia AK; Ling MM; Ong HK J Trop Pediatr; 2020 Dec; 66(6):569-582. PubMed ID: 32577754 [TBL] [Abstract][Full Text] [Related]
28. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. Milton JN; Sebastiani P; Solovieff N; Hartley SW; Bhatnagar P; Arking DE; Dworkis DA; Casella JF; Barron-Casella E; Bean CJ; Hooper WC; DeBaun MR; Garrett ME; Soldano K; Telen MJ; Ashley-Koch A; Gladwin MT; Baldwin CT; Steinberg MH; Klings ES PLoS One; 2012; 7(4):e34741. PubMed ID: 22558097 [TBL] [Abstract][Full Text] [Related]
29. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945 [TBL] [Abstract][Full Text] [Related]
30. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. Passon RG; Howard TA; Zimmerman SA; Schultz WH; Ware RE J Pediatr Hematol Oncol; 2001 Oct; 23(7):448-51. PubMed ID: 11878580 [TBL] [Abstract][Full Text] [Related]
32. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels--the Framingham Heart Study. Lin JP; Schwaiger JP; Cupples LA; O'Donnell CJ; Zheng G; Schoenborn V; Hunt SC; Joo J; Kronenberg F Atherosclerosis; 2009 Sep; 206(1):228-33. PubMed ID: 19389676 [TBL] [Abstract][Full Text] [Related]
33. Bilirubin and Stroke Risk Using a Mendelian Randomization Design. Lee SJ; Jee YH; Jung KJ; Hong S; Shin ES; Jee SH Stroke; 2017 May; 48(5):1154-1160. PubMed ID: 28389615 [TBL] [Abstract][Full Text] [Related]
34. Identifying term breast-fed infants at risk of significant hyperbilirubinemia. Chang PF; Lin YC; Liu K; Yeh SJ; Ni YH Pediatr Res; 2013 Oct; 74(4):408-12. PubMed ID: 23857295 [TBL] [Abstract][Full Text] [Related]
35. A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Zhang Y; Ho K; Keaton JM; Hartzel DN; Day F; Justice AE; Josyula NS; Pendergrass SA; Actkins K; Davis LK; Velez Edwards DR; Holohan B; Ramirez A; Stanaway IB; Crosslin DR; Jarvik GP; Sleiman P; Hakonarson H; Williams MS; Lee MTM Am J Obstet Gynecol; 2020 Oct; 223(4):559.e1-559.e21. PubMed ID: 32289280 [TBL] [Abstract][Full Text] [Related]
36. Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population. Lin R; Wang X; Zhou W; Fu W; Wang Y; Huang W; Jin L Ann Hum Genet; 2011 Mar; 75(2):305-11. PubMed ID: 21309757 [TBL] [Abstract][Full Text] [Related]
38. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554 [TBL] [Abstract][Full Text] [Related]
39. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856 [TBL] [Abstract][Full Text] [Related]
40. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]